Ichthyosis Bullosa of Siemens

Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical DataThe Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients, Offering a Personalized Approach to Dietary Interventions and Safety IRVINE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative diagnostic solutions, announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data. The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data. By deriving a confidence level from the patient's health records including a patient’s elevated immune response to specific food ingredients, including those identified through the Biomerica inFoods® IBS test, or other foods that cause adverse reactions such as gluten intolerance, an IT system could be designed to assess the likelihood of an adverse reaction to a common packaged or prepared food that may contain the food ingredient the patient needs to avoid. Leveraging two sets of data, the invention formulates a safety level for each food item in each specific patient. Consequently, a system could be designed to enable an application (App) on a phone, iPad or computer to screen packaged or prepared foods to identify if the packaged or prepared food contains an ingredient previously identified as harmful to the patient. The technology could also recommend alternative packaged or prepared foods that do not contain the previously identified harmful food ingredient. This patented approach could bridge the gap between healthcare and diet, designed to allow individuals with a variety of medical conditions, allergies, illnesses and food intolerances, whose symptoms are caused or exasperated by consumption of specific food ingredients, to have more control and confidence in their dietary choices. The technology described in this patent that has been issued the notice of allowance can contribute significantly to the digital health sector, ushering in a new era of personalized and preventive healthcare through the power of technology. This patent further strengthens the Company’s robust intellectual property portfolio in the area of science, diet and technology. This is the second patent on this technology the company has received, the first was issued in Japan. "This notice of patent allowance is a step towards a safer, more informed environment where individuals can confidently navigate their dietary choices.” said Zack Irani the CEO of Biomerica. "This recognition from the Chinese Patent Office of the novel and inventive nature of this technology marks a significant step forward in our longer-term ambition of facilitating happier healthier lives globally." The allowed patent application number in China is 201680054790.9 and can be viewed at: https://biomerica.com/inFoods/our-technology/ About inFoods IBS: Unlike traditional IBS treatments that rely on medications to mask symptoms, inFoods® IBS is a personalized and natural treatment approach. The inFoods IBS test is based on a patented technology that identifies the specific foods that can trigger IBS symptoms in individual patients. Once the trigger food(s) have been identified, patients who remove these trigger foods from their diets often experience a significant reduction or elimination in their IBS symptoms. A double blinded placebo controlled clinical study (performed at Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, the University of Michigan, Houston Methodist Hospital, and others), showed the inFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API). Symptom improvement in API for patients in the treatment arm versus the placebo arm was similar to, and in some cases better than, the improvement seen from current IBS drugs in the market, but without the drug side effects. Further information about Biomerica’s patented inFoods® Products and Technology Platform can be found at: https://biomerica.com/infoods/ About Biomerica (NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to: the possibly future development of an information technology system that utilizes artificial intelligence to guide a patient’s dietary choices, and the market opportunities from such a system; the Company’s intellectual property; inFoods® IBS test and other tests; allowance and or clearance of patent applications in China and in other countries; FDA or other regulatory clearance or possible future clearance of products that can be developed and commercialized, utilizing the technology described in the Company’s patent applications; the novel nature of the patented technology and the freedom to operate within the field of use described in patent applications; the development of systems incorporating the patented technology; and the assessment capabilities of a system to detect potential adverse reactions. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of products incorporating the patented technology; regulatory approvals necessary prior to commercialization any of the Company’s products; commercial acceptance of products incorporating the patented technology; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them and such other risks disclosed in the our reports (such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K) filed with the SEC and available on the SEC's Internet site (http://www.sec.gov). Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The Company is under no obligation to update any forward-looking statements after the date of this release. Corporate Contact: Zack Irani-Cohen 949-645-2111 investors@biomerica.com Source: Biomerica, Inc.

HOUSTON, June 13, 2023 /PRNewswire/ -- Houston Acupuncture is pleased to announce the opening of their new clinic in the Greater Houston area. This physician owned practice offers acupuncture and Chinese herbal medicine treatments to the Houston, Bellaire, and Meyerland communities and beyond. "We are excited to offer patients the benefits of Eastern medicine and Chinese herbal therapies, which results in an integrated approach to healthcare," said Dr. David Cherian, the clinic's owner, board-certified physician and licensed acupuncturist. Dr. Cherian obtained his Doctor of Medicine at University of Texas McGovern School of Medicine and has practiced in Houston since 2012. He also obtained a Master of Science in Oriental Medicine degree at American College of Acupuncture and Oriental Medicine. With a unique approach of combined Eastern and Western medicine, Dr. Cherian uses acupuncture and herbal therapies to treat patients suffering from a variety of conditions. "I believe that Eastern medicine can be beneficial in the treatment of chronic pain, insomnia, fatigue, and menstrual disorders, among many others," Cherian continued. The new clinic offers acupuncture services for some heart related issues, COPD, IBS and other GI issues, liver and gallbladder problems, metabolic disorders, joint discomfort and sports injuries, headaches and migraines, and kidney stones. For some patients, visits can last up to two hours and generally include information intake, an examination, herbal tea administration, an acupuncture session, and rest. A regimen of herbal tea use at home may be prescribed for further benefit. Dr. Cherian believes both acupuncture and herbal medicine are built on key principles of Chinese medicine and work together to achieve desired results. "Being a part of the Houston community for the last ten years has been a privilege. Giving back by opening the clinic to serve my neighbors is a great honor and I am looking forward to helping people take back control of their quality of life," Cherian concluded. About Houston Acupuncture: Houston Acupuncture and Primary Care is proud to serve patients in Greater Houston, Bellaire and Meyerland with the benefits of acupuncture services and Chinese herbal therapies. These therapies are proven effective for a variety of issues, including sports injuries, fertility issues, metabolic disorders, Fibromyalgia, GI issues, chronic pain, migraines and more. Visit to learn more. Media Contact: Beth Guide [email protected] 281-389-5117 SOURCE Houston Acupuncture

– LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Approval brings a much-needed option to an estimated 6 million 6-17-year-olds in the U.S.1 affected by this chronic, prevalent condition – BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved LINZESS® (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years-old with functional constipation. LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population. Earlier this year, the FDA granted a 6-month priority review to our supplemental New Drug Application (sNDA), 4 months earlier than the standard review timeline. LINZESS is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States. Functional constipation in children is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass2. The condition affects an estimated 6 million children ages 6-17 years-old in the U.S.1 “When you have a child with functional constipation, it is extremely hard to watch them suffer – spending hours in the bathroom and away from their friends – while there is little you can do as a parent to help them,” said Ceciel T. Rooker, President, International Foundation for Gastrointestinal Disorders. “There has long been a critical need for a new therapeutic option due to lack of approved prescription treatment options, so I’m thrilled that we now have a new prescription option for children that can effectively help address symptoms.” The FDA approval was based on the results of a large, multicenter, double-blind, Phase III study evaluating LINZESS in patients ages 6-17 years-old with functional constipation. A total of 328 patients received the study treatment, randomized in a 1:1 ratio between LINZESS 72 mcg or placebo. In this pivotal study, linaclotide showed a statistically significant and clinically meaningful improvement compared to placebo in 12-week spontaneous bowel movement (SBM) frequency rate (SBMs/week), the primary endpoint. Linaclotide-treated patients demonstrated a greater than two-fold least squares mean change from baseline in SBMs/week (2.6) compared to placebo (1.3) (p<0.0001). The most common adverse event in the pediatric Phase 3 study was diarrhea, which occurred in 4% of LINZESS-treated patients versus 2% in the placebo group. “Pediatric functional constipation is an all-too-common issue that physicians see every day, yet despite the tremendous distress it causes to our patients’ and their families, we haven’t had an FDA-approved prescription treatment to offer until now,” said Jeffrey S. Hyams, M.D., Head, Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children’s Medical Center, Professor of Pediatrics, University of Connecticut School of Medicine. “The approval of LINZESS for the treatment of functional constipation in pediatric patients ages 6-17 years-old is a meaningful advancement for these young patients.” LINZESS is developed and marketed by Ironwood and AbbVie in the United States and has been available since 2012 for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide, the active ingredient in LINZESS, is a first-in-class guanylate cyclase-C (GC-C) agonist and acts locally in the intestine with minimal systemic exposure. Since its launch, it has been used to treat more than 4.5 million unique adult patients with IBS-C and CIC. “Today, Ironwood has broken new ground again in the history of LINZESS, extending the clinical utility of our blockbuster treatment to 6-17-year-olds seeking relief for functional constipation, a debilitating condition,” said Tom McCourt, chief executive officer of Ironwood. “This approval is a momentous step forward in progressing our mission to advance the treatment of GI diseases and redefine the standard of care for GI patients and in ushering in a new era of growth for our company.” Based on this FDA approval, LINZESS 72mcg is now available for the treatment of functional constipation for pediatric patients ages 6-17 years old, with immediate accessibility for most patients building on the class-leading formulary coverage already in place for the brand. About LINZESS (linaclotide) LINZESS® is the #1 prescribed brand in the U.S. for the treatment of adult patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain, constipation, and overall abdominal symptoms of bloating, discomfort and pain associated with IBS-C, as well as the constipation, infrequent stools, hard stools, straining, and incomplete evacuation associated with CIC. LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation. The recommended dose is 290 mcg for IBS-C patients and 145 mcg for CIC patients, with a 72 mcg dose approved for use in CIC depending on individual patient presentation or tolerability. In children with functional constipation aged 6 to 17 years, the recommended dose is 72 mcg. LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood's partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with AstraZeneca for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide. LINZESS Important Safety Information INDICATIONS AND USAGE LINZESS® (linaclotide) is indicated for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults and functional constipation (FC) in children and adolescents 6 to 17 years of age. It is not known if LINZESS is safe and effective in children with FC less than 6 years of age or in children with IBS-C less than 18 years of age. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. CONTRAINDICATIONS • LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. WARNINGS AND PRECAUTIONS Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients. Diarrhea In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBSC and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients and in <1% of 72 mcg LINZESS-treated CIC patients. In children and adolescents 6 to 17 years of age, diarrhea was the most common adverse reaction in 72 mcg LINZESS-treated patients in the FC double-blind placebo-controlled trial. Severe diarrhea was reported in <1% of 72 mcg LINZESS treated patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated. Common Adverse Reactions (incidence ≥2% and greater than placebo) • In IBS-C or CIC adult patients: diarrhea, abdominal pain, flatulence, and abdominal distension. • In FC pediatric patients: diarrhea About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In June 2023, the U.S. Food and Drug Administration also approved LINZESS for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts. We routinely post information that may be important to investors on our website at . In addition, follow us on Twitter and on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s mission, the size of the pediatric 6-17 years-old population in the U.S. affected by functional constipation and the therapeutic benefit to patients suffering from functional constipation. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide and our product candidates; the risk that clinical programs and studies may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical and clinical studies may not be replicated in later studies; the risk that we or our partners are unable to obtain, maintain or manufacture sufficient LINZESS or our product candidates, or otherwise experience difficulties with respect to supply or manufacturing; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the therapeutic opportunities for LINZESS or our product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk that we may never get sufficient patent protection for linaclotide and other product candidates, that patents for linaclotide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that the development of either our clinical pediatric programs in IBS-C and functional constipation are not successful or that any of our product candidates is not successfully commercialized; the risk that our planned investments do not have the anticipated effect on our company revenues; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the impact of the COVID-19 pandemic; and the risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Annual Report on Form 10-K for the year ended December 31, 2022, and in our subsequent SEC filings. 1 U.S. Census, 2017 National Population Projection Tables; Robin, Samantha G. et al, Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria, The Journal of Pediatrics, December 2017; Koppen, I. J. N. et al., Prevalence of Functional Defecation Disorders in Children: A Systemic Review and Meta-Analysis. J Pediatr. 2018. 2 Di Lorenzo C, Hyams JS, Saps M, et al. Chapter 16: Childhood Functional Gastrointestinal Disorders: Child/Adolescent. In: Drossman DA, Chang L, Chey WD, et al. Rome IV: Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction. Raleigh, NC: Rome Foundation; 2016.